目的 探讨谷氨酰胺胶囊联合美沙拉秦肠溶片治疗溃疡性结肠炎的效果。方法 回顾性选取河南省洛阳市偃师人民医院2020年12月—2021年12月收治的溃疡性结肠炎患者137例为研究对象，根据治疗方案分为对照组（n＝69）和试验组（n＝68），对照组给予美沙拉秦肠溶片治疗，每次4片，每天3次，连续治疗1个月；试验组在对照组基础上加用谷氨酰胺胶囊治疗，每次0.5 g，每天3次，连续治疗1个月。对比两组患者治疗前后血清C反应蛋白（CRP）、血沉（ESR）、胰岛素生长因子-Ⅰ（IGF-Ⅰ）、白细胞介素-6（IL-6）、肿瘤坏死因子-α（TNF-α）、转化生长因子-β1（TGF-β1）及溃疡性结肠炎活动指数Sutherland评分，观察临床疗效及不良反应。结果 治疗前，试验组和对照组的血清CRP、ESR、IGF-Ⅰ、IL-6、TNF-α、TGF-β1测定值差异无统计学意义（P＞0.05）；治疗后，两组患者血清CRP、ESR、IL-6、TNF-α测定值均较治疗前显著降低（P＜0.05），且治疗后试验组的血清CRP、ESR、IL-6、TNF-α测定值均显著低于对照组（P＜0.05）；治疗后，两组患者血清IGF-Ⅰ、TGF-β1测定值均较治疗前显著升高（P＜0.05），且试验组的IGF-Ⅰ、TGF-β1测定值均显著高于对照组（P＜0.05）；治疗前，试验组和对照组的Sutherland评分差异无统计学意义（P＞0.05）；治疗后，两组Sutherland评分均较治疗前显著降低（P＜0.05），且试验组的Sutherland评分显著低于对照组（P＜0.05）；治疗后，试验组的整体疗效分布优于对照组，差异具有统计学意义（P＜0.05）；治疗过程中，试验组的不良反应发生率4.41%与对照组的5.80%对比，差异不具有统计学意义（P＞0.05）。结论 谷氨酰胺胶囊联合美沙拉秦肠溶片治疗溃疡性结肠炎较单用美沙拉秦肠溶片具有更好的临床效果。

Objective To investigate the effect of Glutamine Capsule combined with Mesalazine Enteric Coated Tablets in treatment of ulcerative colitis. Methods A total of 137 patients with ulcerative colitis treated in Yanshi People's Hospital of Luoyang, Henan Province from December 2020 to December 2021 were retrospectively selected as the research objects. According to the treatment plan, they were divided into control group (n=69) and experimental group (n=68). Patients in control group were treated with Mesalazine Enteric Coated Tablets, four tablets each time, three times a day, for one month. On the basis of the control group, patients in experimental group were treated with Glutamine Capsule, 0.5 g each time, three times a day, for one month. The serum C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), insulin growth factor-I (IGF-I), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α), transforming growth factor-β1 (TGF-β1), and the activity index of ulcerative colitis Sutherland score were compared between two groups before and after treatment. Clinical efficacy and adverse reactions of two group were observed. Results Before treatment, there was no significant difference in measured values of serum CRP, ESR, IGF-I, IL-6, TNF-α, TGF-β1 in experimental group and control group (P > 0.05). After treatment, measured values of serum CRP, ESR, IL-6, and TNF-α in two groups were significantly lower than those before treatment (P < 0.05), and measured values of serum CRP, ESR, IL-6 and TNF-α in experimental group were significantly lower than those in control group (P < 0.05). After treatment, measured values of serum IGF-I and TGF-β1 in two groups were significantly higher than those before treatment (P < 0.05), and measured values of serum IGF-I and TGF-β1 in experimental group were significantly higher than those in control group (P < 0.05). Before treatment, there was no significant difference in Sutherland score between the experimental group and the control group (P > 0.05). After treatment, the Sutherland score of the two groups was significantly lower than that before treatment (P < 0.05), and the Sutherland score of the experimental group was significantly lower than that of control group (P < 0.05). After treatment, the overall efficacy distribution of experimental group was better than that of control group, and the difference was statistically significant (P < 0.05). During treatment, the incidence of adverse reactions in experimental group was 4.41%, compared with 5.80% in control group, and the difference was not statistically significant (P > 0.05). Conclusion Glutamine Capsule combined with Mesalazine Enteric Coated Tablets has better clinical effect in treatment of ulcerative colitis than Mesalazine Enteric Coated Tablets alone.

R975